Anti-HV118/ IGHV1-18/ IGHV118 functional antibody

Anti-HV118/ IGHV1-18/ IGHV118 functional antibody for cell culture, ELISA & in-vivo assay

Target products collectionGo to IGHV1-18/IGHV1-18 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)


Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-SE0991-Ab-1/ GM-Tg-hg-SE0991-Ab-2Anti-Human IGHV1-18 monoclonal antibodyHuman
GM-Tg-rg-SE0991-Ab-1/ GM-Tg-rg-SE0991-Ab-2Anti-Rat IGHV1-18 monoclonal antibodyRat
GM-Tg-mg-SE0991-Ab-1/ GM-Tg-mg-SE0991-Ab-2Anti-Mouse IGHV1-18 monoclonal antibodyMouse
GM-Tg-cynog-SE0991-Ab-1/ GM-Tg-cynog-SE0991-Ab-2Anti-Cynomolgus/ Rhesus macaque IGHV1-18 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-SE0991-Ab-1/ GM-Tg-felg-SE0991-Ab-2Anti-Feline IGHV1-18 monoclonal antibodyFeline
GM-Tg-cang-SE0991-Ab-1/ GM-Tg-cang-SE0991-Ab-2Anti-Canine IGHV1-18 monoclonal antibodyCanine
GM-Tg-bovg-SE0991-Ab-1/ GM-Tg-bovg-SE0991-Ab-2Anti-Bovine IGHV1-18 monoclonal antibodyBovine
GM-Tg-equg-SE0991-Ab-1/ GM-Tg-equg-SE0991-Ab-2Anti-Equine IGHV1-18 monoclonal antibodyEquine

Size: 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-SE0991-Ab-1/ GM-Tg-hg-SE0991-Ab-2; GM-Tg-rg-SE0991-Ab-1/ GM-Tg-rg-SE0991-Ab-2;
GM-Tg-mg-SE0991-Ab-1/ GM-Tg-mg-SE0991-Ab-2; GM-Tg-cynog-SE0991-Ab-1/ GM-Tg-cynog-SE0991-Ab-2;
GM-Tg-felg-SE0991-Ab-1/ GM-Tg-felg-SE0991-Ab-2; GM-Tg-cang-SE0991-Ab-1/ GM-Tg-cang-SE0991-Ab-2;
GM-Tg-bovg-SE0991-Ab-1/ GM-Tg-bovg-SE0991-Ab-2; GM-Tg-equg-SE0991-Ab-1/ GM-Tg-equg-SE0991-Ab-2
Products NameAnti-IGHV1-18 monoclonal antibody
Formatmab
Target NameIGHV1-18
Protein Sub-locationSecreted Protein/Potential Cytokines
Category of antibodyFACS/Biofunctional Antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)
IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by ELISA with recombinant soluble protein antigen. The biofunction of antibodies are validated with in-vitro assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-IGHV1-18 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenGM-Tg-g-SE0991-Ag-1Recombinant multi-species HV118/ IGHV1-18/ IGHV118 protein


    Target information

    Target IDGM-SE0991
    Target NameIGHV1-18
    Gene ID28468
    Gene Symbol and SynonymsIGHV1-18,IGHV118
    Uniprot AccessionA0A0C4DH31
    Uniprot Entry NameHV118_HUMAN
    Protein Sub-locationSecreted Protein/Potential Cytokines
    Category
    DiseaseN/A
    Gene EnsemblENSG00000211945
    Target ClassificationN/A

    The target: IGHV1-18, gene name: IGHV1-18, also named as IGHV118. Predicted to enable antigen binding activity and immunoglobulin receptor binding activity. Predicted to be involved in several processes, including activation of immune response; defense response to other organism; and phagocytosis. Predicted to be part of immunoglobulin complex, circulating. Predicted to be active in external side of plasma membrane. [provided by Alliance of Genome Resources, Apr 2022].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.